One study suggests that breast cancer cells with FGFR1 alterations that exhibit resistance to CDK4/6 inhibitors and fulvestrant can be overcome by combining the FGFR tyrosine kinase inhibitor (TKI) with CDK4/6 inhibitors and ER antagonists [34]. Here, CDK4 is linked to breast carcinoma.